SEC Filing Summary

Doyle Mittie, Chief Medical Officer at Avalo Therapeutics, Inc., reported a disposition of 1,084 shares of Common Stock on June 10, 2026. The transaction, coded as "F", occurred at a price of $13.10 per share. Following this transaction, Mittie holds 51,776 shares. This disposition includes shares acquired through the Issuer's Employee Stock Purchase Plan, as noted by footnote F1. The filing was made on Form 4, with the signature date of June 12, 2026.